The Covid-19 vaccine being developed by US company Johnson & Johnson has been found to be 66 percent effective at treating moderate and severe infections 28 days after vaccination, a large-scale phase 3 clinical trial has found.
The one-dose vaccine, made by Johnson & Johnson’s Belgian subsidiary Janssen, achieved 72 percent efficacy in preventing Covid-19 in US trials, while the lower success rate of 66 percent was observed in international trials, J&J said on Friday.
Continue reading https://on.rt.com/b0nb